![Renée Aguiar-Lucander](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 887 784 $ in data 30/09/2026
Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA and Egalet A, Independent Director at AC Immune SA, and Director at Ral Capital Ltd. (United Kingdom), all starting in 2025 or ongoing.
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously held roles including Chairman at EnXray Ltd., Director at SpineVision SAS, ImpactRx, Inc., NsGene A, Onyvax Ltd., Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, and SciBase Holding AB. Served as Independent Director at Zyla Life Sciences LLC, MedCap AB, and SciBase Holding AB. Held Independent Non-Executive Director position at Newron Pharmaceuticals SpA from 2006 to 2011.
Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd. Independent Director at Egalet Ltd. in 2013.
Managing Director-Corporate Finance at Lehman Brothers, Inc. (Milan Branch) in 2003.
Partner at 3i Group Plc and 3i Venture Capital.
Chief Operating Officer & Partner at Omega Fund Management UK LLP.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
HANSA BIOPHARMA AB 0,19% | 25/09/2026 | 197.000 ( 0,19% ) | 661 364 $ | 30/09/2026 |
AC IMMUNE SA 0,05% | 11/06/2026 | 51.136 ( 0,05% ) | 133 976 $ | 30/09/2026 |
INVENTIVA SA 0,01% | 01/03/2026 | 24.700 ( 0,01% ) | 92 443 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| HANSA BIOPHARMA AB | Amministratore Delegato | 24/04/2025 |
| INVENTIVA | Direttore/Membro del Consiglio | 22/05/2025 |
| AC IMMUNE SA | Direttore/Membro del Consiglio | 19/06/2025 |
Ral Capital Ltd. (United Kingdom) | Direttore/Membro del Consiglio | - |
Exenta, Inc.
 Exenta, Inc. Packaged SoftwareTechnology Services Develops enterprise resource planning, product lifecycle and supply management software | Presidente | - |
Simparel, Inc.
 Simparel, Inc. Miscellaneous Commercial ServicesCommercial Services Provides global supply chain management solutions | Presidente | - |
Egalet A/S
 Egalet A/S Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceuticals company | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Amministratore Delegato | 01/01/2025 |
| ZYLA LIFE SCIENCES | Direttore/Membro del Consiglio | 10/06/2015 |
| ░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 29 |
|---|---|
3i Group Plc
 3i Group Plc Investment Trusts/Mutual FundsMiscellaneous Operates as an investment company that specializes in private equity and infrastructure | Miscellaneous |
SpineVision SAS
 SpineVision SAS Medical SpecialtiesHealth Technology Develops and markets implants for the treatment of spinal disorders | Health Technology |
ImpactRx, Inc.
 ImpactRx, Inc. Miscellaneous Commercial ServicesCommercial Services Provides health-care sector custom research and promotional consultancy services | Commercial Services |
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Zyla Life Sciences LLC
 Zyla Life Sciences LLC Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops medicines for patients with acute and chronic pain | Health Technology |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapeutics for respiratory diseases | Commercial Services |
INSEAD
 INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MedCap AB
 MedCap AB Medical SpecialtiesHealth Technology Manufactures and sells radiological & ECG equipment, probiotics and nutritional supplements | Health Technology |
Stockholm School of Economics
 Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
SciBase Holding AB
 SciBase Holding AB Medical SpecialtiesHealth Technology Develops point of care device for the detection of malignant melanoma | Health Technology |
Calliditas Therapeutics AB
 Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
NsGene A/S
 NsGene A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic products for the treatment of neurodegenerative disorders | Health Technology |
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Onyvax Ltd.
 Onyvax Ltd. Miscellaneous Commercial ServicesCommercial Services Develops cancer remedy therapies | Commercial Services |
Lehman Brothers, Inc. (Milan Branch)
 Lehman Brothers, Inc. (Milan Branch) Investment Banks/BrokersFinance Security Brokers Dealers And Flotation Companies | Finance |
Sophion Bioscience A/S
 Sophion Bioscience A/S Medical SpecialtiesHealth Technology Develops, manufactures and markets instruments and supplies automated patch clamping | Health Technology |
3i Venture Capital
 3i Venture Capital Investment ManagersFinance 3i VC is an active manager which works as a global team to select approximately twenty early- to late-stage investments per year. They aim to invest in companies with exceptional leadership, entrepreneurial flair, proven technical and business expertise, innovative technology and the vision to create a new market or gain significant share of an existing market. The firm prefers to lead or co-lead investments, and selects opportunities where they can create and realize significant value, take board seats and achieve exits via trade sales or IPOs. They target the healthcare, communications, software and ESAT (electronics, semiconductors and advanced technologies) sectors in Europe, the US and Asia. They invest in a series of funding rounds, separating 'first investments' (in businesses where 3i is not already invested) and 'further investments'. 3i VC actively supports their investee companies, making introductions and offering strategic guidance to accelerate their success. The majority of the firm's venture capital investment is made directly from 3i's balance sheet. | Finance |
Hansa Biopharma AB
 Hansa Biopharma AB Pharmaceuticals: MajorHealth Technology Develops therapies and medicines for the treatment of immunomodulatory | Health Technology |
Simparel, Inc.
Simparel, Inc. Miscellaneous Commercial ServicesCommercial Services Provides global supply chain management solutions | Commercial Services |
BioSilta Ltd.
 BioSilta Ltd. BiotechnologyHealth Technology Provides cell culture technology for laboratory researchers | Health Technology |
Omega Fund Management UK LLP | |
Danish BioVenture General Partner ApS
 Danish BioVenture General Partner ApS Financial ConglomeratesFinance Operates as a general partner and renders investment advice to K/S Danish BioVenture | Finance |
Egalet A/S
Egalet A/S Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceuticals company | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
EnXray Ltd.
 EnXray Ltd. Information Technology ServicesTechnology Services Develops sterilization technology solutions for medical device manufacturing companies | Technology Services |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Engages in biotechnology research and development activities | Commercial Services |
Exenta, Inc.
Exenta, Inc. Packaged SoftwareTechnology Services Develops enterprise resource planning, product lifecycle and supply management software | Technology Services |
Ral Capital Ltd. (United Kingdom) |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
